Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated
pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with
cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated
with colistin alone or colistin combined with meropenem.
Phase:
Phase 4
Details
Lead Sponsor:
Rambam Health Care Campus
Collaborators:
Assaf-Harofeh Medical Center Monaldi Hospital Pisa University Hospital Rutgers Robert Wood Johnson Medical School Sheba Medical Center